Clinical Trials

171 enrolled

Burkitt Lymphoma, Leukemia

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05888493 2026-02-20

LEDA

109 enrolled

Phase 2 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-02-05

Soundtrack-E

Phase 1/2 Recruiting

276 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

174 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, B-Cell

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

50 enrolled

Phase 2 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT06072131 2025-10-23

CRESCENDO

504 enrolled

Lymphoma, T-Cell, Peripheral

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

224 enrolled

Lymphoma, T-Cell, Peripheral

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04824092 2025-09-08

frontMIND

899 enrolled

LymphoidOther solid neoplasm

Lymphoma, Large B-Cell, Diffuse

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Recruiting

480 enrolled

Advanced Solid Tumor

NCT05521087 2025-06-22

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1 Withdrawn

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02303821 2025-06-04

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Completed

141 enrolled 37 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03384654 2025-05-25

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

47 enrolled 22 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

112 enrolled

Lymphoma, B-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05578976 2025-01-23

EPCORE DLBCL-2

900 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1 Completed

111 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

49 enrolled

Neoplasms, Lymphoma, B-Cell

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

117 enrolled 26 charts

Lymphoma, B-Cell

NCT02626455 2024-12-11

CHRONOS-4

Phase 3 Terminated

551 enrolled 32 charts

Lymphoma, Non-Hodgkin

NCT04231448 2024-12-05

DEB

423 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02406092 2024-11-21

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

139 enrolled 14 charts

Lymphoma, Non-Hodgkin

NCT04548700 2024-03-07

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

Phase 1 Terminated

38 enrolled

Lymphoma, T-Cell, Peripheral

NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled 25 charts

Lymphoma, Large B-Cell, Diffuse

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02285062 2023-06-22

ROBUST

570 enrolled 27 charts

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT01332968 2022-08-11

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

1,401 enrolled 40 charts

Lymphoma, Non-Hodgkin

NCT04974996 2022-03-29

LOTIS-8

Phase 1 Withdrawn

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01777152 2021-11-30

ECHELON-2

452 enrolled 16 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01439347 2021-09-09

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Phase 3 Terminated

26 enrolled 7 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

91 enrolled 27 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT00495079 2021-03-05

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

65 enrolled 11 charts

Leukemia, Neoplasms, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02343536 2020-08-28

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Phase 1 Completed

59 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01889069 2020-08-13

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

159 enrolled 24 charts